"IDEAL" vaccines for resource poor settings

Vaccine

Volumn 29, Issue SUPPL. 4, 2011, Pages

  Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Aerosol; EPI; Immunization; Mucosal; Nasal; Needle free; Oral; Smallpox; Vaccines

Indexed keywords

CHOLERA VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TOLL LIKE RECEPTOR; TREHALOSE; TYPHOID VACCINE; VACCINE; VIRUS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

AEROSOL; ARTICLE; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; INJECTION; INNATE IMMUNITY; JET INJECTOR; NEEDLE FREE IMMUNIZATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STORAGE TEMPERATURE; VITRIFICATION;

ADJUVANTS, IMMUNOLOGIC; DEVELOPING COUNTRIES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; INFANT, NEWBORN; VACCINATION; VACCINES;

EID: 84859506292     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.090     Document Type: Article

References (165)

1. Levine O.S., Bloom D.E., Cherian T., de Q.C., Sow S., Wecker J., et al. The future of immunisation policy, implementation, and financing. Lancet 2011, 378(July (9789)):439-448.
2. Vandelaer J., Birmingham M., Gasse F., Kurian M., Shaw C., Garnier S. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 2003, 21(July (24)):3442-3445.
3. Roper M.H., Vandelaer J.H., Gasse F.L. Maternal and neonatal tetanus. Lancet 2007, 370(December (9603)):1947-1959.
4. Masresha B.G., Fall A., Eshetu M., Sosler S., Alleman M., Goodson J.L., et al. Measles mortality reduction and pre-elimination in the African region, 2001-2009. J Infect Dis 2011, 204(July (Suppl. 1)):S198-S204.
5. Mitiku K., Bedada T., Masresha B.G., Kegne W., Nafo-Traore F., Tesfaye N., et al. Progress in measles mortality reduction in Ethiopia, 2002-2009. J Infect Dis 2011, 204(July (Suppl. 1)):S232-S238.
6. Halm A., Yalcouye I., Kamissoko M., Keita T., Modjirom N., Zipursky S., et al. Using oral polio vaccine beyond the cold chain: a feasibility study conducted during the national immunization campaign in Mali. Vaccine 2010, 28(April (19)):3467-3472.
7. Yang H.H., Kilgore P.E., Yang L.H., Park J.K., Pan Y.F., Kim Y., et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001, 183(June (12)):1775-1780.
8. Wiysonge C.S., Nomo E., Mawo J., Ofal J., Mimbouga J., Ticha J., et al. Yellow fever control in Cameroon: where are we now and where are we going?. BMC Med 2008, 3(February (6)):3.
9. Anh D.D., Lopez A.L., Thiem V.D., Grahek S.L., Duong T.N., Park J.K., et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis 2011, 5(January (1)):e1006.
10. Takpa V., Morgah K., Gbedonou P., Eliades M. Distribution of insecticide-treated bednets during an integrated nationwide immunization campaign-Togo, West Africa, December 2004. MMWR Morb Mortal Wkly Rep 2005, 54(October (39)):994-996.
11. Weiss W.M., Burnham G., Winch P.J. Evaluating the experience of GAPS-a methodology for improving quality of mass immunization campaigns in developing countries. J Health Popul Nutr 2009, 27(October (5)):684-695.
12. Arevshatian L., Clements C., Lwanga S., Misore A., Ndumbe P., Seward J., et al. An evaluation of infant immunization in Africa: is a transformation in progress?. Bull World Health Organ 2007, 85(June (6)):449-457.
13. Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010, (October).
14. Adegbola R.A., Secka O., Lahai G., Lloyd-Evans N., Njie A., Usen S., et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366(July (9480)):144-150.
15. Sow S.O., Tapia M.D., Diallo S., Keita M.M., Sylla M., Onwuchekwa U., et al. Haemophilus influenzae type b conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg 2009, 80(6):1033-1038.
16. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999, 77(10):789-800.
17. Kane A., Lloyd J., Zaffran M., Simonsen L., Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999, 77(10):801-807.
18. John T.J., Muliyil J. Introducing pentavalent vaccine in EPI in India: issues involved. Indian J Med Res 2010, 132(October). p. 450-3; author reply 453-5.
19. Griffiths U.K., Korczak V.S., Ayalew D., Yigzaw A. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 2009, 27(February (9)):1426-1432.
20. Levine M.M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 2003, 9(January (1)):99-103.
21. Groot H., Riberiro R.B. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ 1962, 27:699-707.
22. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(November (10)):4969-4973.
23. Mack T.M. Smallpox in Europe, 1950-1971. J Infect Dis 1972, 125(February (2)):161-169.
24. Arita I. Duration of immunity after smallpox vaccination: a study on vaccination policy against smallpox bioterrorism in Japan. Jpn J Infect Dis 2002, 55(August (4)):112-116.
25. + T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(May (5)):710-722.
26. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981, 59(6):895-900.
27. Marin M., Nguyen H.Q., Langidrik J.R., Edwards R., Briand K., Papania M.J., et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clin Infect Dis 2006, 42(February (3)):315-319.
28. Ramsay M.E., Moffatt D., O'Connor M. Measles vaccine: a 27-year follow-up. Epidemiol Infect 1994, 112(April (2)):409-412.
29. Guris D., McCready J., Watson J.C., Atkinson W.L., Heath J.L., Bellini W.J., et al. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr Infect Dis J 1996, 15(December (12)):1082-1086.
30. Syrucek L., Helcl J., Sejda J., Svandova E., Staninec M., Grantova H., et al. Comparative trial of live measles vaccines in Czechoslovakia. Bull World Health Organ 1965, 32(6):779-789.
31. Plotkin S.A. Failures of protection by measles vaccine. J Pediatr 1973, 82(May (5)):908-911.
32. Halsey N.A., Boulos R., Mode F., Andre J., Bowman L., Yaeger R.G., et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985, 313(August (9)):544-549.
33. Anonymous Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. Bull World Health Organ 1967, 36(3):375-384.
34. Querec T.D., Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D. Adv Exp Med Biol 2007, 590:43-53.
35. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9(October (10)):741-747.
36. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(January (1)):116-125.
37. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327(January (5963)):291-295.
38. McKee A.S., MacLeod M.K., Kappler J.W., Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge?. BMC Biol 2010, 8(April):37.
39. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007, 27(November (5)):687-690.
40. Black M., Trent A., Tirrell M., Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines 2010, 9(February (2)):157-173.
41. Rhee E.G., Blattman J.N., Kasturi S.P., Kelley R.P., Kaufman D.R., Lynch D.M., et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 2011, 85(January (1)):315-323.
42. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(October (4)):492-503.
43. Tomai M.A., Vasilakos J.P. T.L.R-7 and -8 agonists as vaccine adjuvants. Expert Rev Vaccines 2011, 10(April (4)):405-407.
44. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239(January (1)):178-196.
45. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(November (10)):6186-6197.
46. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(April (4)):287-293.
47. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9(March (3)):185-194.
48. Belnoue E., Pihlgren M., McGaha T.L., Tougne C., Rochat A.F., Bossen C., et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111(March (5)):2755-2764.
49. Wood N., Siegrist C.A. Neonatal immunization: where do we stand?. Curr Opin Infect Dis 2011, 24(June (3)):190-195.
50. PrabhuDas M., Adkins B., Gans H., King C., Levy O., Ramilo O., et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 2011, 12(March (3)):189-194.
51. Burl S., Townend J., Njie-Jobe J., Cox M., Adetifa U.J., Touray E., et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011, 6(April (4)):e18185.
52. Kollmann T.R., Crabtree J., Rein-Weston A., Blimkie D., Thommai F., Wang X.Y., et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009, 183(December (11)):7150-7160.
53. Kamath A.T., Rochat A.F., Valenti M.P., Agger E.M., Lingnau K., Andersen P., et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One 2008, 3(11):e3683.
54. Lang P.O., Govind S., Mitchell W.A., Siegrist C.A., Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev 2011, 10(July (3)):389-395.
55. Meier S., Bel M., L'huillier A., Crisinel P.A., Combescure C., Kaiser L., et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011, 29(April (19)):3548-3557.
56. Sogaard O.S., Lohse N., Harboe Z.B., Offersen R., Bukh A.R., Davis H.L., et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010, 51(July (1)):42-50.
57. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(July (7)):563-571.
58. Cooper C.L., Davis H.L., Angel J.B., Morris M.L., Elfer S.M., Seguin I., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19(September (14)):1473-1479.
59. Taylor D.N., Treanor J.J., Strout C., Johnson C., Fitzgerald T., Kavita U., et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011, (May).
60. Vindurampulle C.J., Cuberos L.F., Barry E.M., Pasetti M.F., Levine M.M. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine 2004, 22(September (27-28)):3744-3750.
61. Galen J.E., Chinchilla M., Pasetti M.F., Wang J.Y., Zhao L., rciniega-Martinez I., et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 2009, 199(February (3)):326-335.
62. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., Nason M.C., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5(February (2)):e9015.
63. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccine 2010, 6(January (1)):78-83.
64. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December (23)):2209-2220.
65. Kristensen D., Chen D., Cummings R. Vaccine stabilization: research, commercialization, and potential impact. Vaccine 2011, (June).
66. Chen D., Tyagi A., Carpenter J., Perkins S., Sylvester D., Guy M., et al. Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccine 2009, 5(January (1)):26-32.
67. Hilleman M.R. Improving the heat stability of vaccines: problems, needs, and approaches. Rev Infect Dis 1989, 11(May (Suppl. 3)):S613-S616.
68. Schlehuber L.D., McFadyen I.J., Shu Y., Carignan J., Duprex W.P., Forsyth W.R., et al. Towards ambient temperature-stable vaccines: the identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay. Vaccine 2011, 29(July (31)):5031-5039.
69. Ohtake S., Martin R., Saxena A., Pham B., Chiueh G., Osorio M., et al. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 2011, 29(March (15)):2761-2771.
70. Crowe J.H., Crowe L.M., Oliver A.E., Tsvetkova N., Wolkers W., Tablin F. The trehalose myth revisited: introduction to a symposium on stabilization of cells in the dry state. Cryobiology 2001, 43(September (2)):89-105.
71. Iturriaga G., Suarez R., Nova-Franco B. Trehalose metabolism: from osmoprotection to signaling. Int J Mol Sci 2009, 10(September (9)):3793-3810.
72. Crowe J.H. Trehalose as a chemical chaperone: fact and fantasy. Adv Exp Med Biol 2007, 594:143-158.
73. Amorij J.P., Meulenaar J., Hinrichs W.L., Stegmann T., Huckriede A., Coenen F., et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007, 25(August (35)):6447-6457.
74. Huang J., Garmise R.J., Crowder T.M., Mar K., Hwang C.R., Hickey A.J., et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 2004, 23(December (6)):794-801.
75. Alcock R., Cottingham M.G., Rollier C.S., Furze J., De Costa S.D., Hanlon M., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010, 2(February (19)):19ra12.
76. Neutra M.R., Frey A., Kraehenbuhl J.P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996, 86(August (3)):345-348.
77. Czerkinsky C., Anjuere F., McGhee J.R., George-Chandy A., Holmgren J., Kieny M.P., et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999, August (170):197-222.
78. Pasetti M.F., Simon J.K., Sztein M.B., Levine M.M. Immunology of gut mucosal vaccines. Immunol Rev 2011, 239(January (1)):125-148.
79. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(October (Suppl 2)):S22-S27.
80. Clemens J.D., Sack D.A., Harris J.R., et al. Field trial of cholera vaccines in Bangladesh: results from three year follow-up. Lancet 1990, 335:270-273.
81. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(January (1)):11-22.
82. Vesikari T., Matson D.O., Dennehy P., Van D.P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
83. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(January (4)):289-298.
84. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent human-bovine reassortant rotavirus vaccine against severe rotavirus gastroenteritis in sub-Saharan Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
85. Lucas M.E., Deen J.L., von S.L., Wang X.Y., Ampuero J., Puri M., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005, 352(February (8)):757-767.
86. Sur D., Lopez A.L., Kanungo S., Paisley A., Manna B., Ali M., et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009, (October).
87. Levine M.M., Kaper J.B. Live oral cholera vaccine: from principle to product. Bull Inst Pasteur 1995, 93:243-253.
88. Calain P., Chaine J.P., Johnson E., Hawley M.L., O'Leary M.J., Oshitani H., et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine 2004, 22(June (19)):2444-2451.
89. John T.J., Jayabal P. Oral polio vaccination of children in the tropics I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972, 96(4):263-269.
90. Hallander H.O., Paniagua M., Espinoza F., Askelof P., Corrales E., Ringman M., et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002, 21(November (1-2)):138-145.
91. Suharyono Simanjuntak C., Witham N., Punjabi N., Heppner D.G., Losonsky G., et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992, 340:689-694.
92. Czerkinsky C., Holmgren J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunol 2009, 2(July (4)):284-287.
93. Levine M.M., Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998, 351:1375-1376.
94. Chatfield S.N., Fairweather N., Charles I., Pickard D., Levine M., Hone D., et al. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine 1992, 10:53-60.
95. Galen J.E., Gomez-Duarte O.G., Losonsky G.A., Halpern J.L., Lauderbaugh C.S., Kaintuck S., et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 1997, 15(6-7):700-708.
96. Tacket C.O., Galen J., Sztein M.B., Losonsky G., Wyant T.L., Nataro J., et al. Safety and immune responses to attenuated Salmonella enterica Serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 2000, 97(November (2)):146-153.
97. Barry E.M., Gomez-Duarte O., Chatfield S., Pizza M., Rappuoli R., Losonsky G.A., et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect Immun 1996, 64:4172-4181.
98. Lubeck M.D., Davis A.R., Chengalvala M., Natuk R.J., Morin J.E., Molnar-Kimber K., et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 1989, 86(September (17)):6763-6767.
99. Tacket C.O., Losonsky G., Lubeck M.D., Davis A.R., Mizutani S., Horwith G., et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 1992, 10(10):673-676.
100. Galen J.E., Pasetti M.F., Tennant S., Ruiz-Olvera P., Sztein M.B., Levine M.M. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 2009, (May).
101. Curtiss R., Xin W., Li Y., Kong W., Wanda S.Y., Gunn B., et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol 2010, 30(3):255-270.
102. Baudner B.C., O'Hagan D.T. Bioadhesive delivery systems for mucosal vaccine delivery. J Drug Target 2010, 18(December (10)):752-770.
103. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6(October (5)):797-808.
104. Tacket C.O., Reid R.H., Boedeker E.C., Losonsky G., Nataro J.P., Bhagat H., et al. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 1994, 12:1270-1274.
105. Tacket C.O., Mason H.S., Losonsky G., Estes M.K., Levine M.M., Arntzen C.J. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000, 182(1):302-305.
106. Nardelli-Haefliger D., Kraehenbuhl J.P., Curtiss R., Schodel F., Potts A., Kelly S., et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996, 64(December (12)):5219-5224.
107. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338(20):1405-1412.
108. King J.C., Stoddard J.J., Gaglani M.J., Moore K.A., Magder L., McClure E., et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006, 355(December (24)):2523-2532.
109. Davis M.M., King J.C., Moag L, Cummings G., Magder L.S. Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008, 122(July (1)):e260-e265.
110. Levine M.M., Kaper J.B., Black R.E., Clements M.L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 1983, 47:510-550.
111. Gluck R., Mischler R., Durrer P., Furer E., Lang A.B., Herzog C., et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 2000, 181(March (3)):1129-1132.
112. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(February (9)):896-903.
113. Pizza M., Giuliani M.M., Fontana M.R., Douce G., Dougan G., Rappuoli R.L.T.K63 LTR72, two mucosal adjuvants ready for clinical trials. Int J Med Microbiol 2000, 290(October (4-5)):455-461.
114. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4(9):e6999.
115. Agren L.C., Ekman L., Lowenadler B., Nedrud J.G., Lycke N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 1999, 162(February (4)):2432-2440.
116. Lycke N., Bemark M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol 2010, 3(November (6)):556-566.
117. Mills K.H., Cosgrove C., McNeela E.A., Sexton A., Giemza R., Jabbal-Gill I., et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 2003, 71(February (2)):726-732.
118. El-Kamary S.S., Pasetti M.F., Mendelman P.M., Frey S.E., Bernstein D.I., Treanor J.J., et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010, 202(December (11)):1649-1658.
119. Hersh B.S., Carr R.M., Fitzner J., Goodman T.S., Mayers G.F., Everts H., et al. Ensuring injection safety during measles immunization campaigns: more than auto-disable syringes and safety boxes. J Infect Dis 2003, 187(May (Suppl. 1)):S299-S306.
120. Pless R.P., tsi-Enchill A.D., Duclos P. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J Infect Dis 2003, 187(May (Suppl. 1)):S291-S298.
121. Dicko M., Oni A.Q., Ganivet S., Kone S., Pierre L., Jacquet B. Safety of immunization injections in Africa: not simply a problem of logistics. Bull World Health Organ 2000, 78(2):163-169.
122. Kuroiwa C., Suzuki A., Yamaji Y., Miyoshi M. Hidden reality on the introduction of auto-disable syringes in developing countries. Southeast Asian J Trop Med Public Health 2004, 35(December (4)):1019-1023.
123. Simon J.K., Pasetti M.F., Viret J.F., Mischler R., Munoz A., Lagos R., et al. A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults. Hum Vaccine 2007, 3(March (2)):54-58.
124. Dilraj A., Cutts F.T., de Castro J.F., Wheeler J.G., Brown D., Roth C., et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 2000, 355(March (9206)):798-803.
125. Fernandez-de Castro J., Kumate-Rodriguez J., Sepulveda J., Ramirez-Isunza J.M., Valdespino-Gomez J.L. La vacunacion antisarampionosa en Mexico por el metodo de aerosol. Salud Publica Mex Jan 1997, 39(1):53-60.
126. Low N., Kraemer S., Schneider M., Restrepo A.M. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008, 26(January (3)):383-398.
127. Sabin A.B., Flores A.A., Fernandez de Castro J., Sever J.L., Madden D.L., Shekarchi I., et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983, 249(May (19)):2651-2662.
128. Hiremath G.S., Omer S.B. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccine 2005, 1(January (1)):30-36.
129. Valdespino-Gomez J.L., de L.G-G., Fernandez-de-Castro J., Henao-Restrepo A.M., Bennett J., Sepulveda-Amor J. Measles aerosol vaccination. Curr Top Microbiol Immunol 2006, 304:165-193.
130. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals 1997, 25(September (3)):323-338.
131. Dilraj A., Sukhoo R., Cutts F.T., Bennett J.V. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 2007, 25(May (21)):4170-4174.
132. de Swart R.L., Kuiken T., Fernandez-de C.J., Papania M.J., Bennett J.V., Valdespino J.L., et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 2006, 24(September (40-41)):6424-6436.
133. Lin W.H., Griffin D.E., Rota P.A., Papania M., Cape S.P., Bennett D., et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci U S A 2011, 108(February (7)):2987-2992.
134. Hickey A.J., Garmise R.J. Dry powder nasal vaccines as an alternative to needle-based delivery. Crit Rev Ther Drug Carrier Syst 2009, 26(1):1-27.
135. LiCalsi C., Christensen T., Bennett J.V., Phillips E., Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999, 17(March (13-14)):1796-1803.
136. Kissmann J., Ausar S.F., Rudolph A., Braun C., Cape S.P., Sievers R.E., et al. Stabilization of measles virus for vaccine formulation. Hum Vaccine 2008, 4(September (5)):350-359.
137. de Swart R.L., LiCalsi C., Quirk A.V., van A.G., Nodelman V., Alcock R., et al. Measles vaccination of macaques by dry powder inhalation. Vaccine 2007, 25(January (7)):1183-1190.
138. Garcia-Contreras L., Wong Y.L., Muttil P., Padilla D., Sadoff J., Derousse J., et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A 2008, 105(March (12)):4656-4660.
139. Wong Y.L., Sampson S., Germishuizen W.A., Goonesekera S., Caponetti G., Sadoff J., et al. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci U S A 2007, 104(February (8)):2591-2595.
140. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(April (1)):68-89.
141. Hingson R.A., Davis H.S., Rosen M. The historical development of jet injection and envisioned uses in mass immunization and mass therapy based upon two decades experience. Mil Med 1963, 128:516-524.
142. Cohen Reis E., Jacobsen R.M., Tarbell S., Weniger B.G. Taking the sting out of shots: control of vaccination-associated pain and adverse reactions. Pediatr Ann 1998, 27:375-386.
143. Jackson L.A., Austin G., Chen R.T., Stout R., DeStefano F., Gorse G.J., et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001, 19(September (32)):4703-4709.
144. Canter J., Mackey K., Good L.S., Roberto R.R., Chin J., Bond W.W., et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch Intern Med 1990, 150(September (9)):1923-1927.
145. Kelly K., Loskutov A., Zehrung D., Puaa K., LaBarre P., Muller N., et al. Preventing contamination between injections with multiple-use nozzle needle-free injectors: a safety trial. Vaccine 2008, 26(March (10)):1344-1352.
146. Weniger B.G., Papania M.J. Alternative vaccine delivery methods. Vaccines 2008, 1357-1392. Saunders (Elsevier), Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
147. Simon J.K., Carter M., Pasetti M.F., Sztein M.B., Kotloff K.L., Weniger B.G., et al. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector. Vaccine 2011, (October).
148. Jodar L., Duclos P., Milstien J.B., Griffiths E., Aguado M.T., Clements C.J. Ensuring vaccine safety in immunization programmes-a WHO perspective. Vaccine 2001, 19(February (13-14)):1594-1605.
149. Parent dC I., Lang J., Schlumberger M., Vidor E., Soula G., Genet A., et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group. Vaccine 1997, 15(March (4)):449-458.
150. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19(November (7-8)):764-778.
151. Tavel J.A., Martin J.E., Kelly G.G., Enama M.E., Shen J.M., Gomez P.L., et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007, 44(April (5)):601-605.
152. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(December (12)):1650-1660.
153. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature 1998, 391:851.
154. Combadiere B., Liard C. Transcutaneous and Intradermal vaccination. Hum Vaccine 2011, 7(August (8)).
155. Bal S.M., Ding Z., van R.E., Jiskoot W., Bouwstra J.A. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?. J Control Release 2010, 148(December (3)):266-282.
156. Nicolas J.F., Guy B. Intradermal epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7(October (8)):1201-1214.
157. Skountzou I., Kang S.M. Transcutaneous immunization with influenza vaccines. Curr Top Microbiol Immunol 2009, 333:347-368.
158. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002, 70(April (4)):1874-1880.
159. Sow S.O., Diallo S., Campbell J.D., Tapia M.D., Keita T., Keita M.M., et al. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 2005, 24(June (6)):533-537.
160. Tapia M.D., Pasetti M.F., Cuberos L., Sow S.O., Doumbia M.N., Bagayogo M., et al. Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys. Pediatr Infect Dis J 2006, 25(September (9)):819-825.
161. Nokes D.J., Nigatu W., Abebe A., Messele T., Dejene A., Enquselassie F., et al. A comparison of oral fluid and serum for the detection of rubella-specific antibodies in a community study in Addis Ababa, Ethiopia. Trop Med Int Health 1998, 3(April (4)):258-267.
162. Nokes D.J., Enquselassie F., Nigatu W., Vyse A.J., Cohen B.J., Brown D.W., et al. Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bull World Health Organ 2001, 79(7):588-595.
163. Nigatu W., Samuel D., Cohen B., Cumberland P., Lemma E., Brown D.W., et al. Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys. Vaccine 2008, 26(September (37)):4769-4774.
164. Nigatu W., Nokes D.J., Afework A., Brown D.W., Cutts F.T., Jin L. Serological and molecular epidemiology of measles virus outbreaks reported in Ethiopia during 2000-2004. J Med Virol 2006, 78(December (12)):1648-1655.
165. Aylward R.B., Melgaard B., Birmingham M., Lloyd J., Eggers R., Bilhous J., et al. Reaching every child: achieving equity in global immunization. New generation vaccines 2009, 91-100. Informa Healthcare, New York. 4th ed. M.M. Levine, G. Dougan, M.F. Good, M.A. Liu, G.J. Nabel, J.A. Nataro (Eds.).